Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT). The order, which has a value of approximately SEK 7.5 million, is for ClearPoint Prism products and is part of ClearPoint Neuro's full market launch in North America, which began in early June this year, and follows previous orders that CLS received around the turn of the year 2023/2024 totaling approximately SEK 10.5 million.
CLS's collaboration with ClearPoint Neuro Inc aims to develop and commercialize a next-generation fully integrated laser therapy system for high-precision MRI-guided stereotactic laser ablation for use in neurosurgery. Through the integration of the companies' technologies into ONE product solution, users are offered the opportunity to identify, navigate and position sterile laser applicators in the target tissue in a streamlined simplified workflow, followed by MRI-guided monitoring and control of temperature development and ablation progress in the target tissue.
During the spring, the companies have also taken a number of decisive steps to, among other things, further strengthen the product offering and expand the market in the US, steps that include ClearPoint Neuro's US-FDA 510(k) clearance for Prism® Bone Anchor Accessory.
"Recently, we announced a focus on our neurosurgery business area in the coming 12-18 months. This order from ClearPoint Neuro consolidates the strength of CLS's strategic direction and demonstrates a clear demand for CLS and Clearpoint Neuro's combined product offering - ClearPoint Prism Neuro Laser System - ClearPoint Neuro (https://www.clearpointneuro.com/clearpoint-prism-neuro-laser-system/) We now have a joint focus on primarily realizing the full market launch that began in June this year," says Dan J. Mogren, CEO of CLS.
Contact information:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 - (0)705 - 90 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information, please visit: www.clinicallaser.se
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide.
For more information, please visit www.clearpointneuro.com.
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-06-2024 08:30 CET.